MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 106 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,608,925 | -24.6% | 324,090 | +1.7% | 0.00% | – |
| Q2 2023 | $3,460,181 | -24.8% | 318,617 | -52.2% | 0.00% | -100.0% |
| Q1 2023 | $4,601,645 | +71.9% | 666,905 | -0.9% | 0.00% | – |
| Q4 2022 | $2,677,207 | +126.5% | 672,665 | +278.1% | 0.00% | – |
| Q3 2022 | $1,182,000 | +79.4% | 177,905 | +30.7% | 0.00% | – |
| Q2 2022 | $659,000 | -68.1% | 136,066 | -38.5% | 0.00% | – |
| Q1 2022 | $2,067,000 | -66.8% | 221,098 | -57.8% | 0.00% | – |
| Q4 2021 | $6,226,000 | +75.2% | 524,168 | +67.9% | 0.00% | – |
| Q3 2021 | $3,553,000 | -56.6% | 312,233 | -31.5% | 0.00% | -100.0% |
| Q2 2021 | $8,181,000 | -26.8% | 456,053 | -36.9% | 0.00% | -50.0% |
| Q1 2021 | $11,182,000 | -45.6% | 722,385 | -57.1% | 0.00% | 0.0% |
| Q4 2020 | $20,550,000 | +170.3% | 1,684,492 | +184.7% | 0.00% | 0.0% |
| Q3 2020 | $7,602,000 | – | 591,597 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |